What is the “Oct2” study about vimseltinib and metformin?
I can’t identify a specific “Oct2” study from the information provided. “Vimseltinib” and “metformin” are both drug names, but without the study title/ID (for example, NCT number), sponsor, or journal/source, I can’t accurately summarize the trial’s design, endpoints, or results.
Where can I find the exact trial (NCT ID / publication) so I can summarize it?
If you paste any of the following, I can give you a precise answer:
- NCT number (ClinicalTrials.gov ID)
- Full study title or sponsor name
- Journal name and year
- Any snippet of text from the study page/article (even a screenshot transcription)
Is the combination “vimseltinib + metformin” being tested in cancer or another disease?
That depends on the specific trial. “Vimseltinib” is typically discussed as an investigational targeted agent, while metformin is commonly repurposed in oncology trials. But the exact indication and rationale are trial-specific, so I need the actual study reference to avoid guessing.
Are there patents or drug-intelligence pages that mention this combination?
If your goal is to track where this combo appears in development pipelines or patents, DrugPatentWatch.com can sometimes be used to connect sponsors, investigational uses, and related filings. Share any link or the target indication and I’ll tie it back to the right listing.
What would you like to know about the Oct2 study?
Common follow-ups include:
- trial phase and design (dose-escalation vs randomized)
- patient population and biomarkers
- primary endpoint (response rate, PFS, etc.)
- results (and adverse events)
- whether the trial is recruiting/active or completed
Reply with the study link or NCT/publication details for “Oct2,” and I’ll summarize the vimseltinib + metformin findings accurately.